(Q36929331)

English

Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification

scientific article published on 09 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Justin M. Balko

1

object named as

Justin M Balko

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Levi A Garraway

8

object named as

Levi A Garraway

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

author name string

Ingrid A Mayer

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Melinda E Sanders

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Todd W Miller

4

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Maria G Kuba

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Ingrid M Meszoely

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Nikhil Wagle

7

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Carlos L Arteaga

9

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

publication date

9 August 2012

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Molecular Cancer Therapeutics

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

10

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

2301-2305

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

29 September 2017

TNFα-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

29 September 2017

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

29 September 2017

Profiling critical cancer gene mutations in clinical tumor samples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

29 September 2017

Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

29 September 2017

The Catalogue of Somatic Mutations in Cancer (COSMIC)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

29 September 2017

FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

29 September 2017

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

29 September 2017

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

29 September 2017

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

29 September 2017

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

29 September 2017

17 beta-estradiol regulates and v-Ha-ras transfection constitutively enhances MCF7 breast cancer cell interactions with basement membrane

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

29 September 2017

Hormone sensitivity in vitro and in vivo of v-ras-transfected MCF-7 cell derivatives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

27 June 2018

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

4 September 2018

Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

4 September 2018

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

4 September 2018

Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

4 September 2018

Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682668

4 September 2018

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22879364

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1535-7163.MCT-12-0511

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36929331&oldid=1663597492"